Schultz J R, Tu H, Luk A, Repa J J, Medina J C, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf D J, Lustig K D, Shan B
Tularik Inc., South San Francisco, California 94080, USA.
Genes Dev. 2000 Nov 15;14(22):2831-8. doi: 10.1101/gad.850400.
The discovery of oxysterols as the endogenous liver X receptor (LXR) ligands and subsequent gene targeting studies in mice provided strong evidence that LXR plays a central role in cholesterol metabolism. The identification here of a synthetic, nonsteroidal LXR-selective agonist series represented by T0314407 and T0901317 revealed a novel physiological role of LXR. Oral administration of T0901317 to mice and hamsters showed that LXR activated the coordinate expression of major fatty acid biosynthetic genes (lipogenesis) and increased plasma triglyceride and phospholipid levels in both species. Complementary studies in cell culture and animals suggested that the increase in plasma lipids occurs via LXR-mediated induction of the sterol regulatory element-binding protein 1 (SREBP-1) lipogenic program.
氧化甾醇作为内源性肝X受体(LXR)配体的发现以及随后在小鼠中的基因靶向研究提供了强有力的证据,表明LXR在胆固醇代谢中起核心作用。此处鉴定出以T0314407和T0901317为代表的合成非甾体LXR选择性激动剂系列,揭示了LXR的一种新的生理作用。给小鼠和仓鼠口服T0901317表明,LXR激活了主要脂肪酸生物合成基因(脂肪生成)的协同表达,并增加了这两个物种的血浆甘油三酯和磷脂水平。细胞培养和动物实验的补充研究表明,血浆脂质的增加是通过LXR介导的固醇调节元件结合蛋白1(SREBP-1)脂肪生成程序的诱导而发生的。